ADA and esophageal cancer: Two potential lead compounds, catechin and flavoxanthin, were identified to stably bind to ADA.<h4>Discussion</h4>Collectively, these findings suggest a potential role for ADA in the occurrence of esophageal cancer and highlight its possible relevance as a therapeutic target, providing new directions for early intervention and targeted therapy of esophageal cancer.